Cancer management software firm Ziliomics has received backing from the Prospects Oncology Fund to develop its Heliotrope product. The company is working with a number of cancer centers in North America and Europe on clinical trials for patients who have been diagnosed with advanced or metastatic cancer. Financing terms were not disclosed. Heliotrope was designed by genomic experts at the Ontario Institute for Cancer Research. It uses artificial intelligence to process genomic data and enable doctors to make decisions on patients' cancer treatments.
Cancer management software firm Ziliomics has received backing from the Prospects Oncology Fund to develop its Heliotrope product. The company is working with a number of cancer centers in North America and Europe on clinical trials for patients who have been diagnosed with advanced or metastatic cancer. Heliotrope was designed by genomic experts at the Ontario Institute for Cancer Research. It uses artificial intelligence to process genomic data and enable doctors to make decisions on patients' cancer treatments.